Apyx Medical Corporation (NASDAQ:APYX) Q1 2022 Earnings Conference Call May 12, 2022 8:00 AM ET Company Participants Charles Goodwin - President & Chief Executive Officer Tara Semb - Chief Financial Officer, Treasurer & Secretary Conference Call Participants Matthew Hewitt - Craig-Hallum Capital Operator Hello, and welcome, ladies and gentlemen to the First Quarter of 2022 Earnings Call for Apyx Medical Corporation. At this time, all participants have been placed in a listen-only mode. At the end of the com ...

[Part I. Financial Information](index=4&type=section&id=Part%20I.%20Financial%20Information) This section presents the company's unaudited condensed consolidated financial statements and management's analysis of financial performance [Condensed Consolidated Financial Statements (Unaudited)](index=4&type=section&id=Item%201.%20Condensed%20Consolidated%20Financial%20Statements%20(Unaudited)) The unaudited condensed consolidated financial statements for Q1 2022 reflect a widened net loss and a decrease in total assets, impacted by slowed U.S. demand - On March 14, 2022, the FDA issued a Safety Communication warning against the use of the Company's Advanced Energy products outside of their cleared indications, which has led to **slowed demand** for its Helium Plasma Technology in the U.S.[22](index=22&type=chunk)[69](index=69&type=chunk) - The company is actively working with the FDA and filed a 510(k) premarket notification on April 4, 2022, for the use of Renuvion® to improve the appearance of lax skin in the neck and submental region[23](index=23&type=chunk)[70](index=70&type=chunk) [Condensed Consolidated Balance Sheets](index=4&type=section&id=Condensed%20Consolidated%20Balance%20Sheets) The balance sheets as of March 31, 2022, show a decrease in total assets, primarily driven by a reduction in cash and cash equivalents Condensed Consolidated Balance Sheet Highlights (in thousands) | Account | March 31, 2022 | December 31, 2021 | | :--- | :--- | :--- | | **Assets** | | | | Cash and cash equivalents | $26,234 | $30,870 | | Total current assets | $54,811 | $60,737 | | **Total assets** | **$62,997** | **$68,721** | | **Liabilities & Equity** | | | | Total current liabilities | $11,604 | $13,205 | | Total liabilities | $13,154 | $14,712 | | Total equity | $49,843 | $54,009 | | **Total liabilities and equity** | **$62,997** | **$68,721** | [Condensed Consolidated Statements of Operations](index=5&type=section&id=Condensed%20Consolidated%20Statements%20of%20Operations) The statements of operations for Q1 2022 indicate increased sales but a widened net loss due to higher operating expenses Condensed Consolidated Statements of Operations (in thousands, except per share data) | Metric | Q1 2022 | Q1 2021 | | :--- | :--- | :--- | | Sales | $12,493 | $8,638 | | Gross Profit | $8,219 | $5,860 | | Loss from operations | ($5,871) | ($4,745) | | Net loss attributable to stockholders | ($5,945) | ($4,901) | | Basic and diluted loss per share | ($0.17) | ($0.14) | [Condensed Consolidated Statements of Cash Flows](index=7&type=section&id=Condensed%20Consolidated%20Statements%20of%20Cash%20Flows) Cash flow statements for Q1 2022 show increased net cash used in operating activities, leading to a significant decrease in cash and cash equivalents Condensed Consolidated Statements of Cash Flows Highlights (in thousands) | Cash Flow Activity | Q1 2022 | Q1 2021 | | :--- | :--- | :--- | | Net cash used in operating activities | ($4,518) | ($2,052) | | Net cash used in investing activities | ($279) | ($192) | | Net cash provided by (used in) financing activities | $98 | ($61) | | **Net change in cash and cash equivalents** | **($4,636)** | **($2,376)** | | **Cash and cash equivalents, end of period** | **$26,234** | **$39,539** | [Notes to Condensed Consolidated Financial Statements](index=8&type=section&id=Notes%20to%20Condensed%20Consolidated%20Financial%20Statements) Notes provide details on the company's core technology, the impact of FDA communications, legal disputes, and segment performance - The company is involved in a dispute with a former international distributor over contract termination. Management has determined a loss is probable, with an estimated range of $250,000 to $1,000,000, and has accrued the minimum amount of **$250,000**[53](index=53&type=chunk) Sales by Reportable Segment (in thousands) | Segment | Q1 2022 | Q1 2021 | | :--- | :--- | :--- | | Advanced Energy | $10,814 | $7,660 | | OEM | $1,679 | $978 | | **Total** | **$12,493** | **$8,638** | Sales by Geographic Region (in thousands) | Region | Q1 2022 | Q1 2021 | | :--- | :--- | :--- | | Domestic | $7,548 | $5,566 | | International | $4,945 | $3,072 | | **Total** | **$12,493** | **$8,638** | [Management's Discussion and Analysis of Financial Condition and Results of Operations](index=17&type=section&id=Item%202.%20Management's%20Discussion%20and%20Analysis%20of%20Financial%20Condition%20and%20Results%20of%20Operations) Management discusses increased revenue driven by segment growth, a decline in gross margin, and a rise in operating expenses leading to a larger operating loss - The increase in Advanced Energy sales was driven by global utilization-based demand for handpieces and adoption of generator technology in international markets, but was partially offset by **decreased U.S. generator adoption** after the FDA Safety Communication[75](index=75&type=chunk) - Gross profit margin decreased to **65.8%** from **67.8%** in the prior year, primarily due to a higher percentage of lower-margin OEM sales, product and geographic mix within the Advanced Energy segment, and increased shipping costs[79](index=79&type=chunk)[80](index=80&type=chunk) - Operating expenses increased across the board: Professional services rose **50.3%** due to legal and consulting fees, salaries increased **22.0%** from higher compensation, and SG&A grew **46.8%** due to increased advertising, travel, and training expenses[82](index=82&type=chunk)[84](index=84&type=chunk)[85](index=85&type=chunk) - Working capital decreased by **$4.3 million** from December 31, 2021, to **$43.2 million** at March 31, 2022, mainly due to the net loss incurred during the quarter[87](index=87&type=chunk) [Quantitative and Qualitative Disclosures about Market Risk](index=24&type=section&id=Item%203.%20Quantitative%20and%20Qualitative%20Disclosures%20about%20Market%20Risk) The company indicates that there are no applicable quantitative or qualitative disclosures regarding market risk - Not applicable[107](index=107&type=chunk) [Controls and Procedures](index=25&type=section&id=Item%204.%20Controls%20and%20Procedures) Management concluded that disclosure controls and procedures were effective, with no material changes to internal control over financial reporting - Based on an evaluation as of the end of the reporting period, the Chief Executive Officer and Chief Financial Officer concluded that the Company's disclosure controls and procedures were **effective**[109](index=109&type=chunk) - No changes in internal control over financial reporting occurred during the quarter ended March 31, 2022, that have materially affected, or are reasonably likely to materially affect, internal controls[110](index=110&type=chunk) [Part II. Other Information](index=26&type=section&id=Part%20II.%20Other%20Information) This section provides additional information including legal proceedings, risk factors, equity sales, and exhibits [Legal Proceedings](index=26&type=section&id=Item%201.%20Legal%20Proceedings) This section refers to the financial statement notes for details on ongoing legal proceedings, including a dispute with a former distributor - For details on legal proceedings, the report refers to Note 10 of the financial statements[112](index=112&type=chunk) [Risk Factors](index=27&type=section&id=Item%201A.%20Risk%20Factors) No material changes have occurred to the risk factors previously disclosed in the company's latest annual report - No material changes have been made to the risk factors disclosed in the Annual Report on Form 10-K for the year ended December 31, 2021[114](index=114&type=chunk) [Unregistered Sales of Equity Securities and Use of Proceeds](index=28&type=section&id=Item%202.%20Unregistered%20Sales%20of%20Equity%20Securities%20and%20Use%20of%20Proceeds) The company reported no unregistered sales of equity securities or use of proceeds during the reporting period - None[116](index=116&type=chunk) [Exhibits](index=29&type=section&id=Item%206.%20Exhibits) This section lists the exhibits filed with the Form 10-Q, including Sarbanes-Oxley certifications and XBRL data - The exhibits filed with this report include Sarbanes-Oxley certifications (31.1, 31.2, 32.1, 32.2) and XBRL instance documents[118](index=118&type=chunk)

Part I [Business](index=7&type=section&id=Item%201.%20Business) Apyx Medical Corporation is an advanced energy technology company focused on cosmetic and surgical markets, leveraging its Helium Plasma Technology - The company's primary focus is on the cosmetic surgery market with its Renuvion® product, which utilizes innovative **Helium Plasma Technology**[19](index=19&type=chunk) - Apyx operates two reportable segments: Advanced Energy and OEM. For fiscal year 2021, the Advanced Energy segment accounted for **88.6% of total consolidated revenue**, while the OEM segment accounted for the remaining **11.4%**[42](index=42&type=chunk) - The company holds a significant intellectual property portfolio, including **44 issued U.S. patents** and **25 foreign patents**, with numerous pending applications[26](index=26&type=chunk) - Manufacturing operations are located in Clearwater, Florida, and Sofia, Bulgaria. The company has faced some supply chain delays for raw materials but has managed to avoid a meaningful backlog of sales orders[27](index=27&type=chunk)[29](index=29&type=chunk) [Advanced Energy Segment](index=11&type=section&id=Item%201.%20Business-Advanced%20Energy%20Segment) This segment focuses on Renuvion® and J-Plasma® products utilizing Helium Plasma Technology, primarily targeting the cosmetic surgery market - The segment's core technology, **Helium Plasma**, is used in the Renuvion® (cosmetic) and J-Plasma® (surgical) product lines for soft tissue procedures[43](index=43&type=chunk) - As of year-end 2021, the company had a direct sales force of **31 field-based selling professionals** and utilized **2 independent sales agencies**, focusing on the cosmetic surgery market[45](index=45&type=chunk) - The company's products are regulated as **Class II medical devices** by the FDA, requiring 510(k) pre-market notification for clearance[55](index=55&type=chunk)[56](index=56&type=chunk) - On **March 14, 2022**, the FDA issued a Medical Device Safety Communication warning against the use of the company's Advanced Energy products for unapproved indications. The company is evaluating the potential impact of this communication[61](index=61&type=chunk) [OEM Segment](index=15&type=section&id=Item%201.%20Business-OEM%20Segment) The OEM segment designs and manufactures electrosurgical equipment for other medical device companies, including a significant agreement with Symmetry Surgical - The company designs and manufactures electrosurgical equipment and accessories for other medical device companies under OEM agreements[63](index=63&type=chunk) - A significant part of the OEM segment involves a **10-year manufacturing and supply agreement** with Symmetry Surgical, originating from a 2018 asset purchase agreement[63](index=63&type=chunk) [Risk Factors](index=16&type=section&id=Item%201A.%20Risk%20Factors) The company faces significant risks related to regulatory compliance, business operations, and market conditions, including an FDA safety communication - The company is subject to extensive and stringent regulations by the FDA and other international bodies. A recent FDA communication warned against using its products outside of cleared indications, which could adversely affect operations[66](index=66&type=chunk)[70](index=70&type=chunk) - Business operations are exposed to risks from supply chain disruptions for raw materials, reliance on sole-source suppliers, and potential manufacturing interruptions at its Florida and Bulgaria facilities[99](index=99&type=chunk)[100](index=100&type=chunk)[101](index=101&type=chunk) - The company faces risks related to protecting its intellectual property and potential infringement claims from others, which could lead to costly litigation and damage its competitive position[91](index=91&type=chunk)[93](index=93&type=chunk) - The **COVID-19 pandemic** continues to pose risks to business operations, employee availability, and supply chains, with the full extent of its impact remaining uncertain[95](index=95&type=chunk)[96](index=96&type=chunk) - The energy-based medical device industry for aesthetics is highly competitive, with many well-established competitors possessing greater financial resources[105](index=105&type=chunk) [Properties](index=26&type=section&id=Item%202.%20Properties) Apyx Medical operates facilities in Clearwater, Florida, and Sofia, Bulgaria, for its office, manufacturing, warehousing, and research operations - The company owns a **60,000 sq. ft. facility** in Clearwater, Florida[120](index=120&type=chunk) - The company's Bulgarian subsidiary leases a **25,000 sq. ft. facility** in Sofia, Bulgaria[120](index=120&type=chunk) [Legal Proceedings](index=26&type=section&id=Item%203.%20Legal%20Proceedings) The company is involved in legal actions concerning its Helium Plasma technology, which management believes are adequately covered by insurance - The company is involved in legal actions concerning the use of its **Helium Plasma technology**[283](index=283&type=chunk) - Management believes claims are covered by insurance and do not pose a material risk, but acknowledges a potential material impact if damages exceed coverage limits[283](index=283&type=chunk) Part II [Market for Registrant's Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities](index=29&type=section&id=Item%205.%20Market%20for%20Registrant%27s%20Common%20Equity%2C%20Related%20Stockholder%20Matters%20and%20Issuer%20Purchases%20of%20Equity%20Securities) The company's common stock trades on NASDAQ under 'APYX', has never paid cash dividends, and shows strong stock performance against market indices - The company's common stock trades on the NASDAQ Stock Market LLC under the symbol **"APYX"**[125](index=125&type=chunk) - The company has never paid cash dividends and does not plan to in the foreseeable future, retaining earnings for business growth[128](index=128&type=chunk) Securities Authorized for Issuance Under Equity Compensation Plans | Plan Category | Number of Securities to be Issued Upon Exercise (a) | Weighted Average Exercise Price (b) | Number of Securities Remaining Available for Future Issuance (c) | | :--- | :--- | :--- | :--- | | Equity compensation plans approved by security holders | 5,337,691 | $5.97 | 3,130,915 | | Equity compensation plans not approved by security holders | 60,000 | $4.18 | — | | **Total** | **5,397,691** | **$5.95** | **3,130,915** | [Management's Discussion and Analysis of Financial Condition and Results of Operations](index=32&type=section&id=Item%207.%20Management%27s%20Discussion%20and%20Analysis%20of%20Financial%20Condition%20and%20Results%20of%20Operations) In 2021, Apyx Medical experienced a **75.1% revenue increase** driven by its Advanced Energy segment, improved gross margin, and a **net loss of $15.2 million** Sales by Reportable Segment (Year Ended December 31) | (In thousands) | 2021 | 2020 | Change | | :--- | :--- | :--- | :--- | | Advanced Energy | $42,985 | $22,214 | 93.5% | | OEM | $5,532 | $5,497 | 0.6% | | **Total** | **$48,517** | **$27,711** | **75.1%** | Gross Profit (Year Ended December 31) | (In thousands) | 2021 | 2020 | Change | | :--- | :--- | :--- | :--- | | Gross profit | $33,601 | $17,504 | 92.0% | | Gross profit margin | 69.3% | 63.2% | +6.1 p.p. | - The increase in gross profit margin was primarily due to a favorable sales mix, with the higher-margin Advanced Energy segment comprising a larger portion of total sales, and improved manufacturing efficiencies[151](index=151&type=chunk) - Net loss for 2021 was **$15.2 million**, compared to a net loss of **$11.9 million** in 2020. The 2020 result included a significant income tax benefit of **$7.5 million** related to the CARES Act[196](index=196&type=chunk)[161](index=161&type=chunk) - Cash and cash equivalents decreased from **$41.9 million** at the end of 2020 to **$30.9 million** at the end of 2021, with net cash used in operating activities amounting to **$10.4 million**[163](index=163&type=chunk) [Financial Statements and Supplementary Data](index=41&type=section&id=Item%208.%20Financial%20Statements%20and%20Supplementary%20Data) This section presents the audited consolidated financial statements for 2021 and 2020, including balance sheets, statements of operations, cash flows, and detailed notes [Consolidated Balance Sheets](index=43&type=section&id=Item%208.%20Financial%20Statements%20and%20Supplementary%20Data-Consolidated%20Balance%20Sheets) As of December 31, 2021, total assets decreased to **$68.7 million**, primarily due to reduced cash, while total liabilities increased to **$14.7 million** Consolidated Balance Sheet Highlights (as of December 31) | (In thousands) | 2021 | 2020 | | :--- | :--- | :--- | | Cash and cash equivalents | $30,870 | $41,915 | | Total current assets | $60,737 | $66,089 | | Total assets | $68,721 | $74,111 | | Total current liabilities | $13,205 | $9,153 | | Total liabilities | $14,712 | $10,252 | | Total equity | $54,009 | $63,859 | [Consolidated Statements of Operations](index=44&type=section&id=Item%208.%20Financial%20Statements%20and%20Supplementary%20Data-Consolidated%20Statements%20of%20Operations) For 2021, total sales increased **75% to $48.5 million**, leading to a **$15.2 million net loss** attributable to stockholders Consolidated Statement of Operations Highlights (Year Ended December 31) | (In thousands, except per share data) | 2021 | 2020 | | :--- | :--- | :--- | | Sales | $48,517 | $27,711 | | Gross profit | $33,601 | $17,504 | | Loss from operations | $(14,448) | $(20,083) | | Net loss attributable to stockholders | $(15,172) | $(11,896) | | Loss per share - basic and diluted | $(0.44) | $(0.35) | [Consolidated Statements of Cash Flows](index=46&type=section&id=Item%208.%20Financial%20Statements%20and%20Supplementary%20Data-Consolidated%20Statements%20of%20Cash%20Flows) Net cash used in operating activities improved to **$10.4 million** in 2021, with overall cash and cash equivalents decreasing by **$11.0 million** Consolidated Statement of Cash Flows Highlights (Year Ended December 31) | (In thousands) | 2021 | 2020 | | :--- | :--- | :--- | | Net cash used in operating activities | $(10,449) | $(16,066) | | Net cash used in investing activities | $(723) | $(581) | | Net cash provided by (used in) financing activities | $24 | $(73) | | Net change in cash and cash equivalents | $(11,045) | $(16,897) | [Notes to Consolidated Financial Statements](index=47&type=section&id=Item%208.%20Financial%20Statements%20and%20Supplementary%20Data-Notes%20to%20Consolidated%20Financial%20Statements) These notes provide detailed disclosures on accounting policies, segment performance, purchase commitments, and a subsequent FDA safety communication - A subsequent event note discloses that on **March 14, 2022**, the FDA issued a safety communication warning against the use of the company's products outside of their cleared indications. The company is evaluating the potential impact[308](index=308&type=chunk) - As of December 31, 2021, the company had purchase commitments for inventories totaling approximately **$4.9 million**, expected to be fulfilled by the end of 2022[285](index=285&type=chunk) - Sales to one customer in the Advanced Energy segment accounted for **11% of total sales** in 2021. In 2020, one OEM customer represented **10% of total sales**[286](index=286&type=chunk) Segment Performance (Year Ended December 31, 2021) | (In thousands) | Advanced Energy | OEM | Corporate (Other) | Total | | :--- | :--- | :--- | :--- | :--- | | Sales | $42,985 | $5,532 | $— | $48,517 | | Income (loss) from operations | $2,784 | $1,033 | $(18,265) | $(14,448) | [Controls and Procedures](index=70&type=section&id=Item%209A.%20Controls%20and%20Procedures) Management concluded that disclosure controls and internal control over financial reporting were effective as of December 31, 2021, following a new ERP system implementation - Management concluded that the company's disclosure controls and procedures were **effective** as of December 31, 2021[310](index=310&type=chunk) - Management concluded that the company's internal control over financial reporting was **effective** as of December 31, 2021[312](index=312&type=chunk) - A new global **ERP system** was implemented in Q1 2021, leading to changes in internal controls over financial reporting[313](index=313&type=chunk) Part III [Directors, Executive Officers and Corporate Governance](index=71&type=section&id=Item%2010.%20Directors%2C%20Executive%20Officers%20and%20Corporate%20Governance) This section details the biographies of directors and executive officers, highlighting the Board's composition, independence, and committee structure - The Board of Directors is composed of individuals with extensive experience in the medical, engineering, and business fields relevant to the company's operations[316](index=316&type=chunk) - The Board has **seven independent members**, and Lawrence J. Waldman serves as the Lead Independent Director to coordinate the activities of the independent directors[338](index=338&type=chunk)[339](index=339&type=chunk) - The Board has **four standing committees**: Audit, Governance and Nominating, Compensation, and Regulatory Compliance, each composed of independent directors[343](index=343&type=chunk)[346](index=346&type=chunk)[347](index=347&type=chunk)[348](index=348&type=chunk) [Executive Compensation](index=77&type=section&id=Item%2011.%20Executive%20Compensation) The executive compensation program is performance-driven, with 2021 bonuses funded at **125% of target** despite frozen base salaries due to prior year pandemic impacts - The compensation philosophy is guided by three principles: being **performance-driven**, **competitively-positioned**, and **responsibly-governed**[355](index=355&type=chunk) - Due to strong financial performance in 2021, annual incentive bonuses for NEOs were paid out at **125% of their target amounts**[368](index=368&type=chunk)[369](index=369&type=chunk) - Base salaries for NEOs were not increased for fiscal 2021 due to the impact of the **COVID-19 pandemic**[364](index=364&type=chunk) - In January 2021, NEOs received equity awards in the form of stock options, granted at levels representing **50% of the eligible shares** due to the impact of COVID-19[370](index=370&type=chunk) 2021 Summary Compensation Table for NEOs | Name | Year | Salary ($) | Bonus ($) | Option Awards ($) | Total ($) | | :--- | :--- | :--- | :--- | :--- | :--- | | Charles D. Goodwin | 2021 | 450,000 | 421,875 | 701,420 | 1,594,394 | | Moshe Citronowicz | 2021 | 299,000 | 112,125 | 207,828 | 640,320 | | Todd Hornsby | 2021 | 347,000 | 216,875 | 288,650 | 879,310 | | Tara Semb | 2021 | 328,000 | 184,500 | 277,104 | 808,773 | [Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters](index=90&type=section&id=Item%2012.%20Security%20Ownership%20of%20Certain%20Beneficial%20Owners%20and%20Management%20and%20Related%20Stockholder%20Matters) This section details beneficial ownership of common stock, with key institutional holders and officers and directors collectively owning **11.5% of shares** - As of **March 15, 2022**, all officers and directors as a group beneficially owned **11.5% of the company's common stock**[413](index=413&type=chunk) Beneficial Owners of More Than 5% | Name | Percentage of Ownership | | :--- | :--- | | RTW Investments | 9.9% | | William Weeks Vanderfelt | 9.2% | | Archon Capital Management, LLC | 6.4% | | BlackRock, Inc. | 5.8% | | Cowen Financial Products, LLC | 5.5% | [Certain Relationships and Related Transactions and Director Independence](index=93&type=section&id=Item%2013.%20Certain%20Relationships%20and%20Related%20Transactions%20and%20Director%20Independence) The company discloses related party employment and confirms **seven independent Board members** meeting NASDAQ and SEC requirements - Several relatives of the Managing Director of Apyx Bulgaria are employed by the company[420](index=420&type=chunk) - The Board of Directors has **seven members** who are determined to be independent according to NASDAQ and SEC rules[421](index=421&type=chunk) [Principal Accountant Fees and Services](index=93&type=section&id=Item%2014.%20Principal%20Accountant%20Fees%20and%20Services) The company paid its principal accountant, RSM US LLP, a total of **$583,000 in fees** for 2021, including **$485,000 for audit services** Accountant Fees (Year Ended December 31) | (In thousands) | 2021 | 2020 | | :--- | :--- | :--- | | Audit fees | $485 | $420 | | Tax fees | $98 | $— | | **Total fees billed** | **$583** | **$420** | Part IV [Exhibits and Financial Statement Schedules](index=94&type=section&id=Item%2015.%20Exhibits%20and%20Financial%20Statement%20Schedules) This section lists all financial statements, schedules, and exhibits filed as part of the Annual Report on Form 10-K - This section provides a list of all financial statements, schedules, and exhibits filed as part of the Annual Report on Form 10-K[425](index=425&type=chunk)[426](index=426&type=chunk)[427](index=427&type=chunk)

Apyx Medical Corporation (NASDAQ:APYX) Q4 2021 Earnings Conference Call March 17, 2022 8:00 AM ET Company Participants Charles Goodwin – President, Chief Executive Officer & Director Tara Semb – Chief Financial Officer, Treasurer & Secretary Conference Call Participants Matthew Hewitt – Craig-Hallum Matthew O'Brien – Piper Sandler & Co. Russell Cleveland – RENN Capital Group David Turkaly – JMP Securities Operator Please standby. Good morning, ladies, and gentlemen, and welcome to the Fourth Quarter and Fis ...

Apyx Medical Corp (NASDAQ:APYX) Q3 2021 Earnings Conference Call November 11, 2021 5:00 PM ET Company Participants Tara Semb - CFO, Treasurer & Secretary Charles Goodwin - President, CEO & Director Conference Call Participants David Turkaly - JMP Securities Matthew O'Brien - Piper Sandler & Co. Kyle Bauser - Colliers Securities Matthew Hewitt - Craig-Hallum George Cleveland - RENN Capital Group Operator Good afternoon, ladies and gentlemen, and welcome to the Third Quarter of Fiscal Year 2021 Earnings Confe ...

Apyx Medical Corporation (NASDAQ:APYX) Q2 2021 Results Earnings Conference Call August 12, 2021 8:00 AM ET Company Participants Charlie Goodwin - President & Chief Executive Officer Tara Semb - Chief Financial Officer Conference Call Participants Matt Hewitt - Craig-Hallum Russell Cleveland - RENN Capital Kyle Bauser - Colliers Securities Operator Good morning, ladies and gentlemen. And welcome to the Second Quarter of Fiscal Year 2021 Earnings Conference Call for Apyx Medical Corporation. At this time, all ...